FDA-approved
Heart & blood
Pegcetacoplan
Evidence
FDA approved
Class
Complement C3 inhibitor peptide
KEY TAKEAWAY
Pegcetacoplan is a cyclic peptide that blocks complement protein C3, attached to polyethylene glycol to last longer. It is sold as Empaveli and, for the eye, as Syfovre. The FDA approved pegcetacoplan (Empaveli) in 2021 for paroxysmal nocturnal hemoglobinuria and (Syfovre) in 2023 for geographic atrophy, with later approvals for some kidney diseases.
Written by the Veylo editorial team · Updated
November 2026
What it is
Complement C3 inhibitor peptide
Approved for
Paroxysmal nocturnal hemoglobinuria, certain kidney diseases and geographic atrophy of the eye
Key fact
The FDA approved pegcetacoplan (Empaveli) in 2021 for paroxysmal nocturnal hemoglobinuria and (Syfovre) in 2023 for geographic atrophy, with later approvals for some kidney diseases.
Route
Subcutaneous infusion, or injection into the eye
Evidence strength
FDA approved
Pegcetacoplan is a cyclic peptide that blocks complement protein C3, attached to polyethylene glycol to last longer. It is sold as Empaveli and, for the eye, as Syfovre.
It stops the complement system from destroying red blood cells and from damaging cells in the retina.
The FDA approved pegcetacoplan (Empaveli) in 2021 for paroxysmal nocturnal hemoglobinuria and (Syfovre) in 2023 for geographic atrophy, with later approvals for some kidney diseases.
Paroxysmal nocturnal hemoglobinuria, certain kidney diseases and geographic atrophy of the eye.
The injected form carries a boxed warning for serious infections with encapsulated bacteria. The eye injection can cause inflammation and wet macular degeneration.
U.S. FDA prescribing information for Pegcetacoplan. DailyMed, National Library of Medicine.
Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.